Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2026 08:00 ET | Source: Intravacc B.V.

Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships

The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
May 27, 2026 06:37 ET | Source: Bleichmar Fonti & Auld

ADMA Investor Alert: Did ADMA Biologics Mislead Investors about Alleged Channel Stuffing? BFA Law Notifies Investors with Losses of the Pending Securities Fraud Investigation

Did ADMA Biologics Mislead Investors about Alleged Channel Stuffing? BFA Law Notifies Investors with Losses of the Pending Securities Fraud Investigation
May 27, 2026 02:00 ET | Source: Intravacc B.V.

Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships

The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
May 27, 2026 02:00 ET | Source: Intravacc B.V.

Intravacc obtient l’agrément CIR en France pour accompagner ses partenariats en R&D vaccinale

Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et...
May 27, 2026 02:00 ET | Source: Intravacc B.V.

Intravacc erhält Genehmigung der französischen CIR zur Unterstützung von Partnerschaften in der Impfstoffforschung und -entwicklung

Die Zulassung für den Zeitraum 2025–2027 ermöglicht französischen Innovatoren den Zugang zu den Dienstleistungen von Intravacc in den Bereichen Impfstoffentwicklung, analytische Entwicklung und...
May 25, 2026 07:18 ET | Source: Bleichmar Fonti & Auld

$ADMA Shareholder Announcement: ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation

ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation
May 22, 2026 06:43 ET | Source: Bleichmar Fonti & Auld

ADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law’s Ongoing Investigation into the Company’s Potential Misstatements – Contact the Firm if You Lost Money

ADMA Biologics Investors are Notified of BFA Law’s Ongoing Investigation into the Company’s Potential Misstatements – Contact the Firm if You Lost Money
May 20, 2026 08:05 ET | Source: Totaligent

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Totaligent (OTCID:TGNT) successfully closed the strategic acqui-hire of the Aetherium Medical platform and team.
May 20, 2026 06:20 ET | Source: Bleichmar Fonti & Auld

ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law

ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
May 19, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study